0000000000150521

AUTHOR

J. M. Baena

showing 2 related works from this author

Prediction of cardiovascular disease by the framingham-REGICOR equation in the high-risk PREDIMED cohort: Impact of the mediterranean diet across dif…

2017

Background-The usefulness of cardiovascular disease (CVD) predictive equations in different populations is debatable. We assessed the efficacy of the Framingham-REGICOR scale, validated for the Spanish population, to identify future CVD in participants, who were predefined as being at high-risk in the PREvención con DIeta MEDiterránea (PREDIMED) study-a nutrition-intervention primary prevention trial-and the impact of adherence to the Mediterranean diet on CVD across risk categories. Methods and Results-In a post hoc analysis, we assessed the CVD predictive value of baseline estimated risk in 5966 PREDIMED participants (aged 55-74 years, 57% women; 48% with type 2 diabetes mellitus). Major …

MaleMediterranean dietEpidemiologyDisease030204 cardiovascular system & hematologyDiet MediterraneanCohort Studies0302 clinical medicineRisk FactorsMedicine030212 general & internal medicineRisk assessmentOriginal ResearchDiet and NutritionAged 80 and overFramingham Risk ScoreDiabetisDiabetesMiddle AgedPrognosisCardiovascular diseasePrimary PreventionCardiovascular diseasesCardiovascular DiseasesCohortFemaleCardiology and Cardiovascular MedicineFramingham‐REGICOR equationPREDIMEDCardiovascular risk predictionScale (ratio)Risk Assessment03 medical and health sciencesMediterranean dietHumanscardiovascular diseasesAgedProportional Hazards ModelsFramingham-REGICOR equationbusiness.industryMalalties cardiovascularsFeeding BehaviorLifestylePredimedDiabetes Mellitus Type 2SpainAvaluació del riscMediterraneam dietbusinessDemography
researchProduct

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standa…

2019

Abstract Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts). CIBOMA/2004-01_GEICAM/2003-11 is a multinational, randomized phase III trial exploring adjuvant capecitabine (X) after completion of standard treatment in early TNBC pts. Materials and Methods: Patients with operable, node-positive (or node-negative with tumor size ≥ 1 cm), centrally confirmed hormone receptor-negative, HER2-negative early BC, who had received 6–8 cycles (cy) of standard anthracycline and/or taxane-containing chemotherapy or 4 cy of doxorubicin-cyclophosphamide (for node-negative disease) in the (neo)adjuvan…

0301 basic medicineCancer Researchmedicine.medical_specialtyTaxaneAnthracyclinebusiness.industryStandard treatmentHazard ratioCancermedicine.diseaseGastroenterologyCapecitabine03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicinemedicinebusinessTriple-negative breast cancermedicine.drugCancer Research
researchProduct